<DOC>
	<DOCNO>NCT01148069</DOCNO>
	<brief_summary>Standard treatment locally-advanced prostate cancer consist association radiotherapy prostate seminal vesicle ( SV ) androgen deprivation ( AD ) 3 year . This treatment usually precede pelvic lymphadenectomy ass possible extension lymph node prostatic cancer avoid irradiate pelvis case lymph node involvement . However , radiotherapy lead usually 30 % grade ≥2 risk bladder and/or rectal toxicity . This risk particularly depend radiation volume . In aim lower toxicity , treatment study associate : - pelvic lymph node dissection resection seminal vesicle , allow decrease radiation target volume prostate ( irradiate SV ) ; - high-precision radiotherapy technique combine Intensity Modulated Radiation Therapy ( IMRT ) Image-Guided Radiation Therapy ( IGRT ) .</brief_summary>
	<brief_title>Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy ( IMRT-IGRT ) Locally-advanced Prostate Cancers</brief_title>
	<detailed_description>This study target non metastatic prostatic locally-advanced adenocarcinoma high risk local progression metastasis . The standard treatment tumour associate external beam radiation therapy ( EBRT ) 3 year androgen deprivation ( AD ) LH-RH analogue . In absence AD mainly prostate specific antigen ( PSA ) &gt; 10 ng/ml , several randomize study show high dos EBRT increase biochemical control . Nevertheless , escalate dos radiation significantly increase risk rectal and/or urinary toxicity . In order low toxicity irradiation locally-advanced prostate cancer , improve quality life patient , study aim decrease volume irradiate healthy tissue . To carry objective , use double strategy : - Limiting target volume prostate remove seminal vesicle time lymph node dissection , - Using technique high-precision radiation combine Intensity Modulated Radiation Therapy ( IMRT ) Image-Guided Radiation Therapy ( IGRT ) . Based literature , may assume toxicity rate 30 % three year hormonotherapy standard treatment ( i.e . without remove seminal vesicle ) . We make hypothesis 20 % absolute reduction toxicity protocol .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Age &gt; 18 , Prostate adenocarcinoma ( histologically proven ) , Locallyadvanced ( T3a Gleason &gt; 7 PSA ≥ 20 ng/mL ) , Distal half seminal vesicle unaffected MRI , Non metastatic cancer : negative extension assessment ( prostatic pelvic MRI bone scintigraphy ) , Radiotherapy hormonotherapy indication , Medical insurance affiliation , Written inform consent . Noninclusion criterion : Comorbidity medical history contraindicating surgery ( pelvic lymphadenectomy seminal vesicle ablation ) , Contraindication pelvic irradiation , Hip prosthesis , History cancer last 5 year ( except basocellular epithelioma ) , History pelvic irradiation , Person deprive freedom guardianship , Participation another biomedical research . Surgery show lymph node involvement ( pelvic radiation indication ) Surgery without ablation seminal vesicle Surgery positive margin seminal vesicle</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>IMRT-IGRT</keyword>
	<keyword>radiotherapy toxicity</keyword>
	<keyword>seminal vesicle</keyword>
</DOC>